Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02254551
Title Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors SCRI Development Innovations, LLC

multiple myeloma


Bortezomib + Sonidegib

Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Colorado Blood Cancer Institute Denver Colorado 80218 United States Details
Oncology Hematology Care Cincinnati Ohio 45236 United States Details
Tennessee Oncology Chattanooga Tennessee 37404 United States Details
Tennessee Oncology PLLC Nashville Tennessee 37203 United States Details
Texas Transplant Institute/Methodist Healthcare San Antonio Texas 78229 United States Details
*Shaded cells indicate that there was no data available from for the field